Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines

Cancer Genetics

Volumn 206, Issue 5, 2013, Pages 191-205

  Klorin, Geula ^a,b   Rozenblum, Ester ^a   Glebov, Oleg ^a   Walker, Robert L ^a   Park, Yoonsoo ^a   Meltzer, Paul S ^a   Kirsch, Ilan R ^a   Kaye, Frederic J ^a,c   Roschke, Anna V ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Rambam Health Care Campus ^*  (Israel)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Homozygous deletions; Malignant mesothelioma; Oligonucleotide array CGH; Spectral karyotyping; Tumor suppressors

Indexed keywords

ARTICLE; CANCER CELL; CCSER1 GENE; CHROMOSOME 9P; CHROMOSOME REARRANGEMENT; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA MICROARRAY; DUSP7 GENE; GENE DELETION; HOMOZYGOSITY; LINGO2 GENE; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; RBFOX1 GENE; RPL29 GENE; SPECTRAL KARYOTYPING; TETRAPLOIDY; TUMOR SUPPRESSOR GENE;

HOMOZYGOUS DELETIONS; MALIGNANT MESOTHELIOMA; OLIGONUCLEOTIDE ARRAY CGH; SPECTRAL KARYOTYPING; TUMOR SUPPRESSORS;

CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 9; COMPARATIVE GENOMIC HYBRIDIZATION; GENE DELETION; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; SPECTRAL KARYOTYPING;

EID: 84881261418     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2013.04.006     Document Type: Article

References (59)

1. Carbone M., Kratzke R.A., Testa J.R. The pathogenesis of mesothelioma. Semin Oncol 2002, 29:2-17.
2. Howlader N, Noone AM, Krapcho M, etal. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). National Cancer Institute, Bethesda, MD. Available at: Accessed on October,2012. http://seer.cancer.gov/csr/1975_2009_pops09/.
3. Carbone M., Ly B.H., Dodson R.F., et al. Malignant mesothelioma: facts, myths, and hypotheses. JCell Physiol 2012, 227:44-58.
4. Gibas Z., Li F.P., Antman K.H., et al. Chromosome changes in malignant mesothelioma. Cancer Genet Cytogenet 1986, 20:191-201.
5. Popescu N.C., Chahinian A.P., DiPaolo J.A. Nonrandom chromosome alterations in human malignant mesothelioma. Cancer Res 1988, 48:142-147.
6. Tiainen M., Tammilehto L., Mattson K., et al. Nonrandom chromosomal abnormalities in malignant pleural mesothelioma. Cancer Genet Cytogenet 1988, 33:251-274.
7. Sandberg A.A., Bridge J.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma. Cancer Genet Cytogenet 2001, 127:93-110.
8. Kivipensas P., Bjorkqvist A.M., Karhu R., et al. Gains and losses ofDNA sequences in malignant mesothelioma by comparative genomic hybridization. Cancer Genet Cytogenet 1996, 89:7-13.
9. Balsara B.R., Bell D.W., Sonoda G., et al. Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. Cancer Res 1999, 59:450-454.
10. Murthy S.S., Testa J.R. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. JCell Physiol 1999, 180:150-157.
11. Jensen R.H., Tiirikainen M., You L., et al. Genomic alterations in human mesothelioma including high resolution mapping of common regions of DNA loss in chromosome arm 6q. Anticancer Res 2003, 23:2281-2289.
12. Kallioniemi O.P., Kallioniemi A., Piper J., et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 1994, 10:231-243.
13. Zanazzi C., Hersmus R., Veltman I.M., et al. Gene expression profiling and gene copy-number changes in malignant mesothelioma cell lines. Genes Chromosomes Cancer 2007, 46:895-908.
14. Taniguchi T., Karnan S., Fukui T., et al. Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci 2007, 98:438-446.
15. Lindholm P.M., Salmenkivi K., Vauhkonen H., et al. Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH. Cytogenet Genome Res 2007, 119:46-52.
16. Ivanov S.V., Miller J., Lucito R., et al. Genomic events associated with progression of pleural malignant mesothelioma. Int J Cancer 2009, 124:589-599.
17. Serio G., Gentile M., Pennella A., et al. Characterization of a complex chromosome aberration in two cases of peritoneal mesothelioma arising primarily in the hernial sac. Pathol Int 2009, 59:415-421.
18. Cheung M., Pei J., Pei Y., et al. The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival. Oncogene 2010, 29:1633-1640.
19. Jean D., Thomas E., Manie E., et al. Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma. Am J Pathol 2011, 178:881-894.
20. Cheng J.Q., Jhanwar S.C., Klein W.M., et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994, 54:5547-5551.
21. Xiao S., Li D., Vijg J., et al. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995, 11:511-515.
22. Kratzke R.A., Otterson G.A., Lincoln C.E., et al. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. JNatl Cancer Inst 1995, 87:1870-1875.
23. Beroukhim R., Mermel C.H., Porter D., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
24. Bignell G.R., Greenman C.D., Davies H., et al. Signatures of mutation and selection in the cancer genome. Nature 2010, 463:893-898.
25. Ruas M., Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998, 1378:F115-F177.
26. Kamb A., Gruis N.A., Weaver-Feldhaus J., et al. Acell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440.
27. Bianchi A.B., Mitsunaga S.I., Cheng J.Q., et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A 1995, 92:10854-10858.
28. Sekido Y. Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation. Pathol Int 2011, 61:331-344.
29. Cheng J.Q., Lee W.C., Klein M.A., et al. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer 1999, 24:238-242.
30. Murakami H., Mizuno T., Taniguchi T., et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res 2011, 71:873-883.
31. Visser S., Yang X. LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle 2010, 9:3892-3903.
32. Bott M., Brevet M., Taylor B.S., et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011, 43:668-672.
33. Yoshikawa Y., Sato A., Tsujimura T., et al. Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells. Int J Oncol 2011, 39:1365-1374.
34. Yoshikawa Y., Sato A., Tsujimura T., et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 2012, 103:868-874.
35. Testa J.R., Cheung M., Pei J., et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011, 43:1022-1025.
36. Ramos-Nino M.E., Testa J.R., Altomare D.A., et al. Cellular and molecular parameters of mesothelioma. JCell Biochem 2006, 98:723-734.
37. Tomasetti M., Santarelli L. Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application. Cancers 2010, 2:523-548. 10.3390/cancers2020523.
38. Sekido Y. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci 2010, 101:1-6.
39. Solomon D.A., Kim J.S., Ressom H.W., et al. Sample type bias in the analysis of cancer genomes. Cancer Res 2009, 69:5630-5633.
40. Ihaka R., Gentleman R. R: a language for data analysis andgraphics. JComput Graph Stat 1996, 5:299-314. 10.2307/1390807.
41. Aguirre A.J., Brennan C., Bailey G., et al. High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A 2004, 101:9067-9072.
42. Gentleman R., Carey V.J., Huber W., et al. Bioinformatics, and computational biology solutions using R and Bioconductor 2005, Springer, New York.
43. Olshen A.B., Venkatraman E.S., Lucito R., et al. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004, 5:557-572.
44. Venkatraman E.S., Olshen A.B. Afaster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007, 23:657-663.
45. Diskin S.J., Eck T., Greshock J., et al. STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res 2006, 16:1149-1158.
46. Huang D.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
47. Roschke A.V., Tonon G., Gehlhaus K.S., et al. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003, 63:8634-8647.
48. Flejter W.L., Li F.P., Antman K.H., et al. Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes. Genes Chromosomes Cancer 1989, 1:148-154.
49. Hagemeijer A., Versnel M.A., Van Drunen E., et al. Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet 1990, 47:1-28.
50. Bueno R., De Rienzo A., Dong L., et al. Second generation sequencing of the mesothelioma tumor genome. PLoS One 2010, 5:e10612.
51. Illei P.B., Rusch V.W., Zakowski M.F., et al. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 2003, 9:2108-2113.
52. Andersen C.L., Lamy P., Thorsen K., et al. Frequent genomic loss at chr16p13.2 is associated with poor prognosis in colorectal cancer. Int J Cancer 2011, 129:1848-1858.
53. Tada M., Kanai F., Tanaka Y., et al. Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism array in gastric cancer. Cancer Sci 2010, 101:1261-1269.
54. Kotliarov Y., Kotliarova S., Charong N., et al. Correlation analysis between single-nucleotide polymorphism and expression arrays in gliomas identifies potentially relevant target genes. Cancer Res 2009, 69:1596-1603.
55. Scrimieri F., Calhoun E.S., Patel K., et al. FAM190A rearrangements provide a multitude of individualized tumor signatures and neo-antigens in cancer. Oncotarget 2011, 2:69-75.
56. Altomare D.A., Menges C.W., Xu J., et al. Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS One 2011, 6:e18828.
57. Sherr C.J., Weber J.D. The ARF/p53 pathway. Curr Opin Genet Dev 2000, 10:94-99.
58. Toyooka S., Kishimoto T., Date H. Advances in the molecular biology of malignant mesothelioma. Acta Med Okayama 2008, 62:1-7.
59. Roschke A.V., Kirsch I.R. Targeting karyotypic complexity and chromosomal instability of cancer cells. Curr Drug Targets 2010, 11:1341-1350.